Drugs / Ravagalimab
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06402513 | Jun → Oct 2024 | — | AbbVie | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06972446 | Jun 2025 → Feb 2027 expected | rheumatoid arthritis | AbbVie | Recruiting | No outcome recorded |
| Phase 2 | NCT05217472 | Mar 2020 → Apr 2022 | Sjogren syndrome | AbbVie | Withdrawn | No outcome recorded |
| Phase 2 | NCT03695185 | Mar 2019 → Apr 2021 | ulcerative colitis | AbbVie | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ravagalimab | “Ravagalimab, a potent CD40 antagonist is an investigational drug being developed for the treatment of Sjogren's syndrome (SS).” NCT05217472 ↗ |
| Known as | ABBV-323 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298212 ↗ |
| Known as | PR-1629977 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298212 ↗ |
| Action | Inhibit | “a potent antagonist to cluster of differentiation 40 (CD40)” PMID 41920263 ↗ Apr 20261“CD40 ligand antagonist” CHEMBL4298212 ↗ |
| Modality | Monoclonal antibody | “The monoclonal antibody ravagalimab is a potent antagonist to cluster of differentiation 40 (CD40)” PMID 41920263 ↗ Apr 2026 |
| Route | Intravenous | “Ravagalimab 600 mg was administered intravenously (IV).” NCT03695185 ↗ |
| Target | CD40 | “cluster of differentiation 40 (CD40)” PMID 41920263 ↗ Apr 2026 |
| Target | CD40LG | “CD40 ligand antagonist” CHEMBL4298212 ↗ |